A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
暂无分享,去创建一个
Dong-Wan Kim | S. Lim | B. Cho | Sang-We Kim | S. Kang | D. Heo | Heung Tae Kim | Dae-Ho Lee | M. Jung | Jin-Hyuk Choi | H. Shim | J. Choi | Joo‐Hang Kim
[1] G. Yancopoulos,et al. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF , 1999, Oncogene.
[2] D. Hicklin,et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. , 2001, Cancer research.
[3] J. Crowley,et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[5] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[6] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[7] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[8] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[9] Edward S. Kim,et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Dirk Strumberg,et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Manuel Hidalgo,et al. Intracellular signal transduction pathway proteins as targets for cancer therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Herbst,et al. Angiogenesis and lung cancer: prognostic and therapeutic implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[14] R. Herbst,et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Llovet,et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.
[16] Giampietro Gasparini,et al. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications , 2008, Nature Clinical Practice Oncology.
[17] M. Tsuboi,et al. A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[18] L. Pilz,et al. Pemetrexed for the treatment of non-small-cell lung cancer , 2009, Expert review of anticancer therapy.
[19] P. Jänne,et al. Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance , 2009, Clinical Cancer Research.
[20] U. Gatzemeier,et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Santoro,et al. Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells , 2010, Clinical Cancer Research.
[22] W. Leenders,et al. Targeted therapies of cancer: angiogenesis inhibition seems not enough. , 2010, Cancer letters.
[23] N. Ferrara,et al. Autocrine VEGF Signaling Synergizes with EGFR in Tumor Cells to Promote Epithelial Cancer Development , 2010, Cell.
[24] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[25] A. Jemal,et al. Global Cancer Statistics , 2011 .
[26] J. Hainsworth,et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Hainsworth,et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial , 2011, The Lancet.
[28] S. Ha,et al. Distinct clinical features and outcomes in never‐smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement , 2012, Cancer.
[29] G. Scagliotti,et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] G. Giaccone,et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. , 2013, The Lancet. Oncology.
[31] T. Mok,et al. A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015) , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[32] T. Mok,et al. Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer. , 2014, Lung cancer.
[33] Yuanmin Li,et al. Efficacy and safety of docetaxel for advanced non-small-cell lung cancer: a meta-analysis of Phase III randomized controlled trials , 2015, OncoTargets and therapy.
[34] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.